Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
Status:
Completed
Trial end date:
2020-09-15
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well contrast enhanced ultrasound with sulfur
hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants
with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are
injected into a vein in order to help certain organs and tissues show up more clearly on
scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver
cancer compared to ultrasounds without contrast agent.